Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

被引：0
|
作者：
Taiki Hakozaki
Yukio Hosomi
Akihiro Shimizu
Rui Kitadai
Kie Mirokuji
Yusuke Okuma
机构：
[1] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Thoracic Oncology and Respiratory Medicine
[2] National Cancer Center Hospital,Department of Thoracic Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Polypharmacy; Non-small cell lung cancer; Overall survival; Geriatric oncology; Comorbidity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2659 / 2668
页数：9
相关论文
共 50 条
  • [41] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    A D'Incecco
    M Andreozzi
    V Ludovini
    E Rossi
    A Capodanno
    L Landi
    C Tibaldi
    G Minuti
    J Salvini
    E Coppi
    A Chella
    G Fontanini
    M E Filice
    L Tornillo
    R M Incensati
    S Sani
    L Crinò
    L Terracciano
    F Cappuzzo
    British Journal of Cancer, 2015, 112 : 95 - 102
  • [42] Prognostic relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy
    Zhou, Ying
    Zhou, Jinmei
    Shi, Haoyuan
    Hu, Zhiyuan
    Yang, Yanlian
    Jiang, Zefei
    Wang, Tao
    CANCER RESEARCH, 2023, 83 (05)
  • [43] Prospective multi-institutional observational study of antiPD-1/PD-L1 antibody (anti-PD-1/anti-PD-L1) re-treatment in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-1/PD-L1 plus chemotherapy: NJLCG1901
    Tanaka, H.
    Kawashima, Y.
    Saito, S.
    Yoshimura, N.
    Tsukita, Y.
    Saito, R.
    Nakagawa, T.
    Inomata, M.
    Nagashima, H.
    Sugawara, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1652 - S1652
  • [44] Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
    Matias, M.
    Aspeslagh, S.
    Palomar, V.
    Lanoy, E.
    Dercle, L.
    Even, C.
    Ferte, C.
    Hollebecque, A.
    Marabelle, A.
    Massard, C.
    Soria, J-C.
    Postel-Vinay, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer
    Zayas-Soriano, Marta
    Bonete-Sanchez, Manuel
    Campillo-Lopez, Juan
    Marcos-Ribes, Borja
    Hernandez-Guio, Ana
    Teresa Aznar-Saliente, Ma
    FARMACIA HOSPITALARIA, 2021, 45 (01) : 22 - 27
  • [46] Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case-Cohort Study
    El Husseini, Kinan
    Piton, Nicolas
    De Marchi, Marielle
    Gregoire, Antoine
    Vion, Roman
    Blavier, Pierre
    Thiberville, Luc
    Baste, Jean-Marc
    Guisier, Florian
    CANCERS, 2021, 13 (19)
  • [47] PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (14) : 1667 - 1678
  • [48] Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
    Shen, Xuxia
    Li, Yuan
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1817 - 1818
  • [49] The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer
    Lisberg, Aaron
    Garon, Edward B.
    JAMA ONCOLOGY, 2016, 2 (05) : 571 - 572
  • [50] Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
    Shen, Xuxia
    Li, Yuan
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1817 - 1818
12345